Q1 2021 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Ladies and gentlemen, welcome to the Sobi presentation for Q1 results.
(Operator Instructions)
I will now hand over to Guido Oelkers, CEO. Please go ahead.
()-&
Yes. Thank you so much, and welcome to Sobi's Q1 conference. We are in an exciting period for the company. And before going into the presentation, a quick reminder of the forward-looking statement as per usual. I'm joined today by Henrik Stenqvist, CFO of the company; and Ravi Rao, the Head of R&D.
Q1 is a quarter that deserves a second look and I'll come back to this in a moment. However, first I want to draw your attention to what we have achieved during the first 3 months. Substantial growth in our launch business. Particular, with Doptelet, we more than tripled in Q1 versus last year. We had -- we stayed competitive in our Haemophilia business and showed significant patient growth versus Q1 last year. We had strong earnings in the quarter, and we delivered
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
